Stepping in to supply the market during US shortages of generic Adderall (mixed amphetamine salts), combined with a “more favorable pricing environment” for US generics, have helped to boost Lannett in its financial first quarter ended 30 September, allowing the firm to generate what it described as “better than expected financial results.”
Nevertheless, Lannett’s sales still slid by more than a quarter to $75.1m and the company reported an operating loss of $13.0m for the three-month period. But CEO Tim Crew put a positive spin on the results, especially given that he had warned at the start of 2022 of a generic pricing environment that had “intensified beyond historical norms and our recent expectations
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?